The US Food and Drug Administration (FDA) continues to evaluate reports about the side effects of medications such as “Ozempic,” “Mounjaro,” and “Wegovy” on hair loss, and suicidal thoughts among people who take them.
These drugs, known as GLP-1 receptor agonists, to treat diabetes or weight loss, have been approved for use. They include semaglutide under the brand names Ozempic, Rybelsus, and Wegovy; Liragotide, which carries the brand names Saxenda and Victoza; and “tirzepatide”, known commercially as “Mounjaro” and “Zepbound”.
These drugs mimic GLP-1, a hormone made naturally in the body, whose roles include slowing the passage of food through the stomach.
As a result, the US Food and Drug Administration is seeking to “evaluate the need for regulatory action” after the agency’s Adverse Event Reporting System (FAERS) received reports of alopecia or hair loss; Accidentally inhaling or breathing in while eating or drinking; And suicidal ideation by those who use these medications.
The website noted that “the US Food and Drug Administration has identified a potential safety problem, but this does not mean that it has identified a causal relationship between the drug and the listed risks.”
Therefore, the FDA urged people who use these medications and have questions or concerns about side effects to contact their health care provider.
Accordingly, the agency confirmed For CNN It “monitors the safety of drugs throughout their life cycle, including post-approval. In addition, the US Food and Drug Administration maintains a system of post-marketing surveillance and risk assessment programs to identify and evaluate adverse events that did not arise during the drug development process.”
Therefore, if newly indicated safety markers are identified, FDA will take appropriate action, if any, after a comprehensive review of the available data.”
These actions may include requesting label modifications, or developing a risk assessment and mitigation strategy, a program that helps ensure a drug’s benefits outweigh its risks.
On the other hand, some research has linked GLP-1 agonists to serious digestive problems such as stomach paralysis, pancreatitis, and intestinal obstruction, although the risks of these events appear to be rare.
European regulators have also been investigating the risk of suicidal thoughts in people taking these drugs for several months, although it is not clear whether the drugs cause these events, or if they are linked to other underlying conditions.
2024-01-05 10:54:00
#Alopecia #suicidal #thoughts #Additional #reports #diabetes #weight #loss #medications
